查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931187

乳房切片耗材市场（依产品类型、影像技术、最终用户和应用划分）－全球预测，2026-2032年

Breast Biopsy Consumable Market by Product Type, Imaging Technique, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年乳房切片耗材市场价值为 6.2199 亿美元，预计到 2026 年将成长至 6.596 亿美元，年复合成长率为 6.96%，到 ​​2032 年将达到 9.9652 亿美元。

关键市场统计数据
基准年 2025 6.2199亿美元
预计年份：2026年 6.596亿美元
预测年份 2032 9.9652亿美元
复合年增长率 (%) 6.96%

现代医疗保健中影响乳房切片耗材决策的临床、技术和采购驱动因素的综合框架

乳房切片耗材产业处于诊断准确性和以患者为中心的护理的关键交汇点。新的影像技术、改进的医疗设备人体工学以及不断发展的临床路径正在共同重塑组织采集的方式。临床医生和采购团队越来越重视能够缩短手术时间、提高检体充足率和最大限度减少患者不适的工具，而医疗机构管理者在选择设备时则需要在营运效率和安全要求之间取得平衡。

影像技术的整合、设备创新、日益严格的监管以及患者体验的提升，正在推动变革性变化，并重新定义竞争格局。

乳房切片耗材市场格局正受到多项重大变革的影响，这些变革正在重塑临床实践和供应链的优先事项。首先，成像技术的进步正在加速跨模态相容性的发展。曾经针对单一模态优化的设备，如今正被改造以在超音波、立体定位和磁振造影等多种环境下可靠运作。这种转变正在推动筹资策略优先选择能够在多种手术环境下保持性能稳定的设备。

美国近期推出的关税措施正在推动整个价值链进行供应链重组、采购多元化和采购韧性提升。

近期美国贸易政策引发的关税变动，为依赖全球供应链的乳房切片耗材生产商和经销商带来了新的挑战。关税调整影响了进口零件和成品的到岸成本结构，促使企业重新评估其筹资策略、供应商关係和库存模式。为此，许多企业正在进行敏感度分析，以确定哪些零件最易受关税风险影响，以及哪些生产过程可以转移到其他地区。

透过細項分析洞察，将产品类型、影像方式、医疗环境和临床应用联繫起来，从而帮助制定有针对性的商业和临床策略。

細項分析揭示了不同产品类型、影像方式、最终用户和临床应用领域中截然不同的应用趋势。产品细分包括切片检查盒、取芯针、弹簧式装置和真空抽吸针，其中取芯针又细分为 14G、16G 和 18G 三种规格。这些细分反映了临床医生对检体大小、操作控制和与影像技术相容性的偏好。当组织学保真度至关重要时，通常会选择用于较大直径取芯的装置；而较小规格的装置则更适用于微创手术和门诊流程。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势将影响采用模式、监管协调和商业化方法。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的产品应用、监管预期和采购惯例均有显着影响。在美洲，私人和公共支付方、已建立的诊断网络以及对门诊手术效率的高度重视等因素影响着决策，从而推动了兼顾临床性能和运营效率的设备的普及。该地区报销框架和临床指南的更新也推动了对能够提供可重复诊断样本的解决方案的需求。

竞争格局的特点是透过产品创新、证据累积、整合服务模式和稳健的供应链实现长期差异化。

乳房切片耗材领域的竞争格局体现了技术创新、临床证据累积和策略合作的融合。主要企业正致力于产品迭代改进，以提高检体品质和手术效率，同时拓展培训和服务范围，确保临床信心。与影像平台供应商的合作以及与诊断工作流程的整合正成为关键的差异化因素，因为收购方优先考虑能够无缝支援现有影像模式工作流程的设备。

领导企业导向的实用策略蓝图：整合跨模式产品创新、供应链韧性、证据产生和灵活的商业模式

为了充分利用不断变化的临床需求和供应链现状，产业领导者应携手采取一系列策略行动，协调产品开发、商业性执行和营运韧性。首先，透过在产品蓝图中优先考虑跨模态相容性，并确保设备能够在磁振造影 (MRI)、立体定位和超音波环境下正常运行，来扩大目标临床使用者群体并简化采购决策。将设计创新与和临床医生共同开发的倡议相结合，以加速产品推广应用并确保其在实际应用中的有效性。

严谨的混合方法研究设计，整合了临床文献、专家访谈、工具性分析和供应链诊断，以得出检验的研究结果。

本分析的研究结合了系统性文献综述、专家访谈、设备规格分析和供应链评估，旨在得出切实可行的见解。同行评审的临床文献和监管申报文件为理解设备安全性和手术结果奠定了基础，同时对技术规格进行了评估，以确定其在不同显像模式和临床工作流程中的兼容性。此外，还对介入放射科医生、乳房外科医生、采购人员和设备管理人员进行了平行访谈，从而揭示了设备选择和操作限制的实际考虑因素。

临床、营运和监管动态的整合，定义了该领域持续竞争优势的策略要务。

乳房切片耗材产业正向性能主导市场转型，设备选择主要取决于临床结果、模式相容性和操作效率。针头设计、真空辅助功能和人体工学设计的创新，正满足对可重复检体品质和改善病患体验的需求。同时，贸易政策变化和监管预期等外部压力，也促使各机构优先考虑供应链透明度和基于实证医学的选择标准。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章乳房切片耗材市场（依产品类型划分）

  • 切片检查盒
  • 芯针
    • 14G
    • 16G
    • 18G
  • 弹簧加载装置
  • 吸辅助针

第九章乳房切片耗材市场（依诊断影像技术划分）

  • 磁共振引导
  • 立体定位
  • 超音波引导

第十章 依最终用户分類的乳房切片耗材市场

  • 门诊手术中心
  • 诊断中心
  • 医院

第十一章 依应用分類的乳房切片耗材市场

  • 癌症检测
  • 囊肿穿刺
  • 纤维腺瘤的评估

第十二章 各地区乳房切片耗材市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章乳房切片耗材市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国乳房切片耗材市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国乳房切片耗材市场

第十六章 中国乳房切片耗材市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Biomedical Ltd.
  • Advanced Sterilization Products
  • AprioMed AB
  • Argon Medical Devices, Inc.
  • Becton, Dickinson and Company
  • Biomedical Polymers, Inc.
  • Biomedical Srl
  • BIP Biomed. Inst. & Prod. GmbH
  • CR Bard, Inc.
  • Cardinal Health, Inc.
  • CP Medical
  • Devicor Medical Products, Inc.
  • GALLINI Srl
  • Hologic, Inc.
  • INRAD, Inc.
  • Integra LifeSciences Holdings Corporation
  • Labtician Ophthalmics, Inc.
  • Merit Medical Systems, Inc.
  • Ranfac Corp.
  • SOMATEX Medical Technologies GmbH
  • STERYLAB Srl
  • Sterylab Srl
  • Teleflex Incorporated
  • Tsunami Srl
Product Code: MRR-7B550E008DA7

The Breast Biopsy Consumable Market was valued at USD 621.99 million in 2025 and is projected to grow to USD 659.60 million in 2026, with a CAGR of 6.96%, reaching USD 996.52 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 621.99 million
Estimated Year [2026] USD 659.60 million
Forecast Year [2032] USD 996.52 million
CAGR (%) 6.96%

Comprehensive framing of clinical, technological, and procurement drivers shaping decision-making for breast biopsy consumables in modern healthcare

The breast biopsy consumable sector occupies a critical position at the intersection of diagnostic precision and patient-centered care. New imaging capabilities, refinements in device ergonomics, and evolving clinical pathways are collectively reshaping how tissue sampling is performed. Clinicians and procurement teams increasingly prioritize tools that reduce procedural time, improve specimen adequacy, and minimize patient discomfort, while healthcare administrators weigh device selection against operational efficiency and safety requirements.

Against this backdrop, the ecosystem supporting breast biopsy consumables encompasses product manufacturers, imaging providers, hospitals, diagnostic centers, and ambulatory surgical settings. Technological convergence is apparent: needle design, vacuum assistance, and spring-loaded mechanisms are being optimized to integrate with ultrasound, stereotactic, and MRI-guided workflows. As a result, adoption dynamics are driven not only by device-level performance but also by modality compatibility, reimbursement pathways, and the need for standardized clinical protocols that support reproducible outcomes.

Understanding this environment requires a nuanced view of clinical utility, procurement decision drivers, and regulatory oversight. This report synthesizes those elements, emphasising actionable intelligence for clinical leaders, product developers, and institutional buyers to align investments with evolving standards of care and patient expectations.

Transformative shifts driven by imaging convergence, device innovation, regulatory rigor, and patient experience that redefine competitive priorities

The landscape for breast biopsy consumables is being transformed by several high-impact shifts that reconfigure clinical practice and supply chain priorities. First, imaging-driven refinements are accelerating cross-modal compatibility; devices once optimized for a single modality are now being adapted to perform reliably across ultrasound, stereotactic, and MRI settings. This transition encourages procurement strategies that favour devices delivering consistent performance across multiple procedural contexts.

Second, clinician preference is moving toward devices that provide both procedural efficiency and superior specimen quality. Innovations in needle geometry, vacuum-assisted extraction, and spring-loaded mechanisms are reducing the need for repeat procedures and improving diagnostic confidence. Consequently, hospitals and diagnostic centers are investing in devices that reduce downstream costs associated with inconclusive samples and repeat visits.

Third, regulatory scrutiny and quality standards continue to raise the bar for device validation and post-market surveillance. Manufacturers must demonstrate robust clinical evidence, comprehensive training programs, and traceability across supply chains to meet institutional purchasing criteria. Finally, a stronger emphasis on patient experience-driven by patient advocacy and value-based care models-is influencing device selection, with an eye toward minimally invasive options that shorten recovery and support outpatient care pathways. These converging forces are creating a more integrated, performance-led marketplace where clinical outcomes and operational efficiency are mutually reinforcing.

How recent United States tariff actions are prompting supply chain redesigns, sourcing diversification, and procurement resilience measures across the value chain

Recent tariff developments originating from United States trade policy have introduced new layers of complexity for manufacturers and distributors of breast biopsy consumables that rely on global supply chains. Tariff adjustments affect the landed cost structure of imported components and finished devices, encouraging firms to reassess sourcing strategies, supplier relationships, and inventory models. In response, many organizations are conducting sensitivity analyses to determine which components are most exposed to tariff risk and which production steps can be reallocated to alternative jurisdictions.

These trade measures also prompt strategic recalibrations in contract negotiations and pricing strategies. Suppliers are increasingly transparent about origin of manufacture and are layering contractual protections to manage cost volatility. Procurement teams, in turn, are seeking longer lead times and flexible procurement terms to mitigate the risk of sudden cost shifts. The cumulative impact of tariff policy is not limited to direct procurement costs; it affects clinical deployment timelines when manufacturers adjust manufacturing footprints or reroute logistics to avoid tariff exposure.

Moreover, tariff-driven supply chain reconfigurations heighten the importance of supplier diversification and nearshoring as tools to improve resilience. Healthcare providers and device companies that invest in supply chain visibility, inventory buffers, and strategic supplier partnerships will be better positioned to ensure uninterrupted access to essential consumables. Transitional strategies that prioritize continuity of care while managing cost pressures are essential in this evolving trade environment.

Segment-driven insights linking product types, imaging modalities, care settings, and clinical uses to inform targeted commercial and clinical strategies

Segmentation analysis reveals differentiated adoption dynamics across product types, imaging modalities, end users, and clinical applications. Product segmentation distinguishes Biopsy Kit, Core Needle, Spring Loaded Device, and Vacuum Assisted Needle, with the Core Needle further detailed as 14G, 16G, and 18G variants; these distinctions map to clinician preferences for sample size, procedural control, and compatibility with imaging techniques. Devices designed for larger core diameters are often chosen when histological fidelity is paramount, whereas finer gauges support minimally invasive approaches and outpatient workflows.

Imaging technique segmentation-MRI Guided, Stereotactic, and Ultrasound Guided-shapes device design and procurement decisions. MRI-guided procedures demand materials and device constructs compatible with magnetic environments and extended procedural times, while stereotactic approaches emphasize spatial precision within mammography suites. Ultrasound-guided workflows prioritize real-time visualization and device ergonomics that support rapid tissue targeting. Each modality therefore influences the prioritized device attributes and the training required for safe and effective use.

End user segmentation including Ambulatory Surgical Centers, Diagnostic Centers, and Hospitals highlights divergent procurement drivers and operational constraints. Ambulatory settings pursue devices that enable short procedures and rapid turnover, diagnostic centers focus on throughput and repeatability, and hospitals require versatility across inpatient and outpatient contexts. Application segmentation spanning Cancer Detection, Cyst Aspiration, and Fibroadenoma Evaluation clarifies clinical indications that determine device selection, specimen handling protocols, and follow-up pathways. Understanding how these segments intersect provides a nuanced lens for product positioning, clinician training, and commercialization planning.

Regional dynamics across Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adoption patterns, regulatory alignment, and commercialization approaches

Regional dynamics exert a pronounced influence on product adoption, regulatory expectations, and procurement practices across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, decisions are shaped by a mix of private and public payers, well-established diagnostic networks, and a strong focus on outpatient procedural efficiency; these factors promote adoption of devices that balance clinical performance with operational throughput. Reimbursement frameworks and clinical guideline updates in the region also drive demand for solutions that deliver reproducible diagnostic samples.

In Europe, Middle East & Africa, regulatory harmonization, local clinical practices, and varying infrastructure capacity yield heterogeneous adoption patterns. In some markets within this region, centralized hospital systems and national procurement programs favour standardization and long-term supplier partnerships, whereas other markets prioritise flexibility and local manufacturing partnerships. Asia-Pacific displays rapid technology adoption in urban tertiary centres alongside an expanding footprint of ambulatory and diagnostic facilities; this divergence creates opportunities for scalable devices that can be adapted for both high-volume metropolitan hospitals and resource-conscious outpatient clinics.

Across all regions, manufacturers and distributors must align commercialization strategies with local regulatory requirements, clinician training expectations, and healthcare delivery models. Regional market entrants that tailor value propositions to local care pathways and payer landscapes will be better able to secure clinician endorsement and institutional adoption.

Competitive landscape characterized by product innovation, evidence generation, integrated service models, and supply chain robustness driving long-term differentiation

Competitive activity in the breast biopsy consumable space reflects a blend of technical innovation, clinical evidence generation, and strategic partnerships. Leading firms are investing in iterative product enhancements that improve specimen quality and procedural ergonomics while expanding training and service offerings to secure clinical trust. Partnerships with imaging platform providers and integration into diagnostic workflows are becoming key differentiators as buyers prioritise devices that seamlessly support established modality workflows.

In addition to product features, market positioning increasingly rests on post-market support, training programs, and evidence generation. Organizations that invest in multicentre clinical studies, peer-reviewed publications, and robust clinician education demonstrate higher levels of institutional acceptance. Distribution and service networks also play an outsized role: rapid access to consumables, spare parts, and local technical assistance can determine whether a device is preferred for high-volume settings.

Emerging competitors often target niche applications or seek to undercut incumbents through price competitiveness, but sustainable advantage tends to accrue to companies that combine product reliability with comprehensive clinical support and supply chain resilience. For stakeholders evaluating partners or acquisition targets, attention to regulatory histories, quality systems, and evidence portfolios provides valuable insight into long-term viability.

Actionable strategic roadmap for leaders to integrate cross-modal product innovation, supply chain resilience, evidence generation, and flexible commercial models

To capitalise on shifting clinical needs and supply chain realities, industry leaders should adopt a coordinated set of strategic actions that align product development, commercial execution, and operational resilience. First, prioritize cross-modal compatibility in product roadmaps so devices function reliably across MRI, stereotactic, and ultrasound environments, thereby broadening the addressable clinical base and simplifying procurement decisions. Coupling design innovation with clinician co-creation initiatives will accelerate adoption and ensure real-world usability.

Second, strengthen supplier diversification and nearshoring options to reduce exposure to tariff and logistics volatility. Establishing transparent supplier scorecards and contingency sourcing protocols will improve operational continuity. Third, invest in rigorous clinical evidence and education programs that demonstrate procedural efficiency, specimen adequacy, and patient experience benefits; such evidence supports procurement discussions and reimbursement engagement. Fourth, develop flexible commercial models that accommodate ambulatory surgical centers, diagnostic centers, and hospitals through tailored service bundles, training, and inventory solutions.

Finally, embed digital enablement in product and service offerings by providing procedural analytics, training platforms, and inventory management tools that reinforce device value propositions. Leaders who integrate clinical performance, supply chain resilience, and supportive services will differentiate in a marketplace increasingly defined by outcomes and operational efficiency.

Rigorous mixed-methods research design integrating clinical literature, expert interviews, device analysis, and supply chain diagnostics for validated insights

The research underpinning this analysis combined systematic literature review, expert interviews, device specification analysis, and supply chain diagnostics to generate actionable insights. Peer-reviewed clinical literature and regulatory filings provided a foundation for understanding device safety profiles and procedural outcomes, while technical specifications were evaluated to map compatibility across imaging modalities and clinical workflows. In parallel, interviews with interventional radiologists, breast surgeons, procurement leads, and device managers informed practical considerations around device selection and operational constraints.

A supply chain diagnostic approach assessed sourcing dependencies, logistics pathways, and tariff exposure to identify vulnerability points and potential mitigation strategies. Competitive profiling drew on product portfolios, clinical evidence, and service capabilities to assess differentiation and positioning. The methodology emphasized triangulation across sources so that conclusions are anchored in convergent evidence rather than single data points. Throughout, data validation steps including expert review and cross-checking against technical documentation were applied to ensure analytical rigor and reliability of insights.

Synthesis of clinical, operational, and regulatory dynamics that define strategic imperatives for sustainable competitive advantage in the sector

The breast biopsy consumable domain is evolving into a performance-driven market where device selection is governed by clinical outcomes, modality compatibility, and operational efficiency. Innovations in needle design, vacuum assistance, and ergonomics are aligning with demands for reproducible specimen quality and enhanced patient experience. At the same time, external pressures including trade policy shifts and regulatory expectations are prompting organizations to prioritize supply chain transparency and evidence-based selection criteria.

Stakeholders who align product development with clinician needs, invest in robust clinical validation, and embed resilient sourcing strategies will be best positioned to influence care pathways and procurement decisions. Additionally, a focus on scalable training and service models will accelerate adoption across diverse care settings from ambulatory centers to tertiary hospitals. Ultimately, sustainable competitive advantage in this sector will accrue to organizations that demonstrate measurable clinical value and deliver consistent operational support that integrates seamlessly into established diagnostic workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Biopsy Consumable Market, by Product Type

  • 8.1. Biopsy Kit
  • 8.2. Core Needle
    • 8.2.1. 14G
    • 8.2.2. 16G
    • 8.2.3. 18G
  • 8.3. Spring Loaded Device
  • 8.4. Vacuum Assisted Needle

9. Breast Biopsy Consumable Market, by Imaging Technique

  • 9.1. MRI Guided
  • 9.2. Stereotactic
  • 9.3. Ultrasound Guided

10. Breast Biopsy Consumable Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals

11. Breast Biopsy Consumable Market, by Application

  • 11.1. Cancer Detection
  • 11.2. Cyst Aspiration
  • 11.3. Fibroadenoma Evaluation

12. Breast Biopsy Consumable Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Biopsy Consumable Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Biopsy Consumable Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Breast Biopsy Consumable Market

16. China Breast Biopsy Consumable Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Advanced Biomedical Ltd.
  • 17.6. Advanced Sterilization Products
  • 17.7. AprioMed AB
  • 17.8. Argon Medical Devices, Inc.
  • 17.9. Becton, Dickinson and Company
  • 17.10. Biomedical Polymers, Inc.
  • 17.11. Biomedical Srl
  • 17.12. BIP Biomed. Inst. & Prod. GmbH
  • 17.13. C. R. Bard, Inc.
  • 17.14. Cardinal Health, Inc.
  • 17.15. CP Medical
  • 17.16. Devicor Medical Products, Inc.
  • 17.17. GALLINI S.r.l.
  • 17.18. Hologic, Inc.
  • 17.19. INRAD, Inc.
  • 17.20. Integra LifeSciences Holdings Corporation
  • 17.21. Labtician Ophthalmics, Inc.
  • 17.22. Merit Medical Systems, Inc.
  • 17.23. Ranfac Corp.
  • 17.24. SOMATEX Medical Technologies GmbH
  • 17.25. STERYLAB S.r.l.
  • 17.26. Sterylab S.r.l.
  • 17.27. Teleflex Incorporated
  • 17.28. Tsunami S.r.l.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST BIOPSY CONSUMABLE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY BIOPSY KIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 14G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 16G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY 18G, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SPRING LOADED DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY VACUUM ASSISTED NEEDLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY MRI GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY ULTRASOUND GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CYST ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY FIBROADENOMA EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 132. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST BIOPSY CONSUMABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY CORE NEEDLE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY IMAGING TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA BREAST BIOPSY CONSUMABLE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)